Terms: = Prostate cancer AND HOXA9, HOX1, 3205, ENSG00000078399, HOX1G, P31269 AND Prognosis
4 results:
1. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients.
Janke F; Angeles AK; Riediger AL; Bauer S; Reck M; Stenzinger A; Schneider MA; Muley T; Thomas M; Christopoulos P; Sültmann H
Clin Epigenetics; 2022 Dec; 14(1):163. PubMed ID: 36461127
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive Landscape of HOXA2, hoxa9, and HOXA10 as Potential Biomarkers for Predicting Progression and prognosis in prostate cancer.
Song YP; Xian P; Luo H; Dai JY; Bai Y; Li Y; Tang XL
J Immunol Res; 2022; 2022():5740971. PubMed ID: 35372588
[TBL] [Abstract] [Full Text] [Related]
3. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment.
Sarno F; Nebbioso A; Altucci L
Epigenetics; 2020 May; 15(5):439-453. PubMed ID: 31790636
[TBL] [Abstract] [Full Text] [Related]
4. Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression.
Chen JL; Li J; Kiriluk KJ; Rosen AM; Paner GP; Antic T; Lussier YA; Vander Griend DJ
Clin Cancer Res; 2012 Aug; 18(16):4291-302. PubMed ID: 22723371
[TBL] [Abstract] [Full Text] [Related]
